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Abstract
Background: The Hippo signaling acts as a tumor-suppressor pathway that negatively regulates TAZ and YAP.
Increasing evidence supports the activation of TAZ and YAP in breast cancer. Moreover, the Hippo pathway
is involved in the biology of non-neoplastic cells residing in the tumor microenvironment. On this basis, we
herein assessed TAZ and YAP in triple-negative breast cancer and its surrounding microenvironemnt in order to
investigate their impact on pathological complete response (pCR) and tumor recurrence.
Methods: Sixty-one triple-negative breast cancer patients treated with neoadjuvant chemotherapy were retrospectively
evaluated. TAZ and YAP were assessed by immunohistochemistry and classified as positive or negative according to
the percentage of tumor-expressing cells, cellular localization, and staining intensity. TAZ and YAP expression was also
evaluated in non-lymphocytic stromal cells, tumor-infiltrating lymphocytes (TILs) and endothelial cells. The Pearson’s
Chi-squared test of independence was used to test the association between TAZ/YAP and clinical-molecular factors.
A multivariate logistic regression model was generated to identify variables impacting pCR. The Kaplan-Meier method
and the log-rank test were used for estimating and comparing survival curves. Cox proportional regression models were
built to evaluate the risk of recurrence for the variables considered. Internal validation was carried out with a re-sampling
without replacement method.
Results: We did not observe any impact on pCR rate when TAZ and YAP were addressed singularly. Conversely, the
combined expression of YAP in tumor cells and non-lymphocytic stromal cells was an independent predictor of reduced
pCR rate in the multivariate model (OR 7.13, 95 % CI: 1.23–41.41, p = 0.029). Next, the combined expression of TAZ and
YAP was associated with shorter disease-free survival (DFS) in multivariate analysis (HR 3.07, 95 % CI: 1.24–7.61, p= 0.016).
The robustness of these findings were internally validated.
Conclusions: The combined expression of YAP in TNBC cells and in the surrounding stroma seems to be associated with
a decreased likelihood to achieve pCR. Conversely, the combined expression of TAZ and YAP in tumor cells conferred
poor survival outcomes.
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Background
The Hippo pathway is a regulator of tissue growth that
in neoplastic diseases is considered a tumor suppressor
signaling [1]. The Hippo core module, composed by the
kinases MST1, MST2, LATS1, LATS2 and the adaptor
proteins SAV1, MOB1A, MOB1B, carries out an in-
hibitory phosphorylation of the Hippo transducers
TAZ and YAP. When the pathway is switched off, or
when pathway-extrinsic cues activate TAZ and YAP,
they translocate to the nucleus [2]. Here, after inter-
actions with other factors, TAZ and YAP promote the
transcription of target genes [2].
In breast cancer (BC), the activation of the TAZ/YAP-
transcriptional program feeds a number of tumor-
promoting functions [3]. An important oncogenic
function of TAZ relates to its association with BC stem
cells (BCSCs) [4, 5]. Cordenonsi et al. first reported on
the connection between TAZ and self-renewal of BCSCs
[4]. Our group enforced this link [5]. Characterization of
a collection of patient-derived BCSCs and related xeno-
grafts enabled us to mechanistically describe the involve-
ment of TAZ in chemoresistance and metastatic spread
[5]. Conversely, the involvement of YAP in BC is am-
biguous, considering that both tumor-promoting and
tumor-suppressive functions have been proposed [3].
These latter are based on preclinical evidence describing
a negative regulation of YAP mediated by AKT [6], and
the interaction between YAP and p73 that leads to the
transcription of proapoptotic genes [7].
Beyond cancer cells, the Hippo pathway is involved in
the biology of other cell types residing in the tumor
microenvironment. Maintenance of cancer-associated
fibroblast (CAFs) properties was tied to YAP activation
[8]. Moreover, a non-canonical, immune-related Hippo/
MST pathway orchestrates activation, trafficking, and
homing of T cells [9].
The growing body of evidence connecting TAZ and
YAP to BC biology prompted us to translate preclinical
findings into clinical investigations. As a general principle,
the focus was placed on the neoadjuvant setting, which is
increasingly exploited for the identification of cancer
biomarkers. This is rooted in the link between an inter-
mediate endpoint, namely pathological complete response
(pCR) after neoadjuvant chemotherapy (NACT), and
survival outcomes [10]. In the HER2-positive background,
we have already reported on a significant association
between elevated TAZ expression and pCR in Luminal-
type/HER2-positive tumors [11].
Herein we present results from triple-negative BC
(TNBC), the most aggressive BC form. TAZ and YAP
were assessed by immunohistochemistry in pretreatment
biopsies related to 61 stage II-III TNBC patients who re-
ceived anthracycline-taxane-based NACT. TAZ and YAP
were assessed in tumor cells, and in non-neoplastic cells
including endothelial cells, non-lymphocytic stromal
cells, and tumor-infiltrating lymphocytes (TILs).
This study was planned with the following goals: i)
describing the topographic expression of TAZ/YAP in
TNBC, ii) investigating the association between TAZ/
YAP and pCR, iii) exploring the connection between
TAZ/YAP and survival outcomes, and iv) providing clues
on the role of YAP as an oncogene or an oncosuppressor
in TNBC.
Methods
Study participants and procedures
Sixty-one TNBC patients treated with NACT were
included in this retrospective analysis. Patients were
considered eligible if NACT was completed, data were
available on clinical-pathological features including
stage, estrogen receptor (ER) status, progesterone recep-
tor (PgR) status, tumor grade, Ki-67 and pCR, and tu-
mors did not show HER2 overexpression/amplification
according to ASCO-CAP guidelines. In this analysis, six
patients with weak expression (≤10) of either ER or PgR
in diagnostic biopsies were included, given that in these
tumors hormone receptor status switched from weak
positivity to negativity in residual cancers. For these tu-
mors, a basal-like molecular portrait may be hypothe-
sized in light of the fact that up to 20 % of basal-like
cancers express the ER [12]. Stromal TILs were assessed
as recently reported by the International TILs Working
Group [13].
NACT consisted in anthracycline-taxane-based
chemotherapy regimens, either with a concomitant
or sequential schedule, as detailed elsewhere [14].
Seven patients received adjuvant chemotherapy. pCR
was defined as no residual invasive tumor in both
breast and axilla, irrespective of the presence of
ductal carcinoma in situ (ypT0/is ypN0).
While the impact of TAZ/YAP on pCR rate was
evaluated in the entire cohort (N = 61), the impact
of TAZ/YAP expression on survival outcomes was
evaluated in 57 patients, considering that we were
unable to retrieve this information for four patients.
Disease-free survival (DFS) was defined as time
from diagnosis until locoregional, invasive contrala-
teral or distant recurrence, or death due to any
cause.
The immunohistochemical assessment of TAZ and YAP
was performed in formalin-fixed paraffin-embedded tis-
sues using the monoclonal antibody (MoAb) anti-TAZ
(M2-616, BD Pharmingen) at the dilution of 1:400 and
the MoAb anti-YAP (H-9, Santa Cruz) at the dilution of
1:200.
For the evaluation of TAZ and YAP in cancer cells,
their expression was reported both in terms of percent-
age of tumor-expressing cells and staining intensity (0 =
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absent, 1+ = weak, 2+ =moderate, and 3+ = strong). For
tumors with both nuclear and cytoplasmic expression,
staining intensity and percentage of tumor-expressing
cells were independently assessed in, and reported for,
the two cellular compartments.
Tumors were classified as negative (TAZneg, YAPneg)
or positive (TAZpos, YAPpos) on the basis of their cellular
localization, staining intensity, and percentage of tumor-
expressing cells. TAZ/YAP positivity was defined as a
distinct, moderate (2+) or strong (3+) nuclear immuno-
reactivity in ≥10 % of neoplastic cells [5].
For the evaluation of TAZ/YAP in the tumor micro-
environment, the three main cellular components,
namely endothelial cells, non-lymphocytic stromal cells
and TILs, were morphologically identified. For each com-
partment, TAZ/YAP expression was considered positive
when cells exhibited a distinct homogeneous/heteroge-
neous immunoreactivity, irrespectively of the subcellular
localization. Faintly staining cells or positive cells located
in the tumor margin or in areas with poor morphology
were not included in the analysis. The related molecular
variables were designated as following: TAZstroma and
YAPstroma, TAZTILs and YAPTILs, TAZend and YAPend.
Two investigators (ADB and CE) blinded to treatment
outcomes independently evaluated immunoreactivity.
Discordant cases were further reviewed by a third obser-
ver (MM).
This retrospective study has been conducted in ac-
cordance with the Declaration of Helsinki and approved
by the Ethic Committee of “Regina Elena” National
Cancer Institute of Rome, the coordinating centre.
Written informed consents were secured before chemo-
therapy from any single participant.
Statistical analysis
Descriptive statistics were used to summarize study par-
ticipants’ characteristics. Continuous data were reported
as mean and standard deviation, and categorical data by
frequencies and percentage values.
The Pearson’s Chi-squared test of independence (2-
tailed) and the Fisher Exact test, when appropriate, were
used to assess the relationship between TAZ/YAP and
clinical-molecular features and pCR. Survival curves
were estimated with the Kaplan-Meier method, and the
log-rank test was used for comparisons.
To identify independent predictors of pCR, a multi-
variate logistic regression model was generated with var-
iables that tested significant at the univariate assessment,
and the related estimates reported as Odds Ratio (OR)
and 95 % Confident Interval (CI). To identify independ-
ent predictors of DFS, multivariate Cox proportional
hazard models were built with the same modality, and
the related estimates reported in terms of Hazard Ratios
(HR) and 95 % CI.
The risk to obtain an overfitting multivariate model
for DFS was controlled through a re-sampling without
replacement technique, envisioning the generation of
100 less-powered datasets obtained by randomly remov-
ing ~20 % of the original sample. For each simulation,
the Cox model was repeated and the replication rate was
calculated.
We considered statistically significant p values less
than 0.05. Statistical analyses were carried out using
SPSS software (SPSS version 21, SPSS Inc., Chicago, IL,
USA).
Results
Clinical-pathological features and treatment outcomes
related to the 61 TNBC patients included in this study
are summarized in Table 1. All the bioptic samples ex-
amined in this study contained at least 30 % of neoplas-
tic cells.
As aforementioned, activation of TAZ/YAP promotes
multiple oncogenic function in BC cells [3]. TAZ/YAP
have also been linked to the function of non-neoplastic
cells residing in the tumor microenvironment, and po-
tentially affecting therapeutic resistance and survival
outcomes. An immune-related, non-canonical Hippo/
MST pathway is emerging as a multifaceted regulator of
adaptive immunity, being essential for proper T cell de-
velopment and function [9]. Next, TAZ/YAP are central
for survival of endothelial cells in response to changes in
cell geometry [2]. Finally, YAP was reported as a key
Table 1 Baseline characteristics and treatment outcome of
TNBC patients treated with neoadjuvant chemotherapy (N = 61)
Characteristics N (%)
Age at diagnosis
Mean ± SD 49.8 ± 11.4
Median (min-max)[IQrange] 48.4 (25.6–76.6) [44.3–58.3]
Stage
II 21 (34.4)
III 40 (65.6)
Ki-67
Mean ± SD 58.2 ± 24.7
Median (min-max)[IQrange] 60 (10–90) [40–80]
Grade
1–2 22 (36.1)
3 39 (63.9)
Chemotherapy
Sequential 52 (85.2)
Concomitant 9 (14.8)
Pathological complete response
Yes 18 (29.5)
No 43 (70.5)
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factor for the maintenance of CAFs that, in turn, have
been associated with a variety of tumor-promoting func-
tions, even including resistance to chemotherapy [8]. On
this basis, we investigated the impact of TAZ/YAP on
therapeutic outcomes by considering their topographic
expression, namely their presence/absence in cancer
cells, non-lymphocytic stromal cells, endothelial cells,
and TILs.
The expression of TAZ and YAP in tumor cells (and
their cellular localization), non-lymphocytic stromal
cells, endothelial cells, and TILs is summarized in
Additional file 1: Table S1. Representative immunohisto-
chemical staining patterns are illustrated in Fig. 1.
When TAZ and YAP were evaluated for their associ-
ation with established clinical-molecular features and
pCR, the only associations that resulted significant were
Fig. 1 Representative examples of immunohistochemical expression of TAZ and YAP in TNBC patients. a a tumor expressing TAZ in tumor cells
and in non-lymphocytic stromal cells. b a tumor expressing TAZ exclusively in cancer cells. c a tumor expressing YAP in tumor cells and in
non-lymphocytic stromal cells. d a tumor expressing YAP in tumor cells, but not in non-lymphocytic stromal cells. Black arrows indicate
the stromal compartment. The corresponding H&E staining are also showed (e–h). Scale bar = 30 μm
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between TAZpos and higher stage (p = 0.030) and YAPpos
and higher grade (p = 0.028) (Additional file 2: Table S2).
Thus, neither TAZ nor YAP, independently on whether
they were considered in tumor cells or in non-neoplastic
cells, showed a significant association with pCR when
singularly considered.
We therefore investigated whether the expression of
TAZ or YAP in cancer cells, together with their expres-
sion in non-cancerous cells, was able to identify the cat-
egory of patients with reduced pCR rate. As reported in
Table 2, the YAPpos/YAPstroma phenotype was signifi-
cantly associated with reduced pCR rate at the uni- and
multivariate assessment (OR 5.23, 95 % CI: 1.06–25.70,
p = 0.042, and OR 7.13, 95 % CI: 1.23–41.41, p = 0.029,
respectively).
We next investigated whether TAZ and/or YAP im-
pacted DFS. At a median follow-up of 31 months, 19
events were recorded in the 57 evaluable patients. As
previously specified in the “Study Participants and pro-
cedures” section, post-surgical follow up data were not
available for four patients. The pattern of disease recur-
rence is shown in Additional file 3: Table S3. Visceral
and/or skeletal metastasis developed in 11 out of the 19
relapsed patients, and two patients had brain metastases.
Again, neither TAZ nor YAP were associated with DFS
when individually analyzed (data available upon request).
Reasoning that, analogously to pCR rate, the combin-
ation of different markers may have been more inform-
ative, we then tested different biomarker combinations.
With this strategy, we observed that the co-expression
of TAZ and YAP in tumor cells (TAZpos/YAPpos) was
associated with tumor recurrence (p = 0.004; panel a
in Fig. 2), and that these patients exhibited shorter
DFS (p = 0.004; panel b in Fig. 2). Consistently, as
shown in Table 3, the TAZpos/YAPpos phenotype was
associated with an increased risk of relapse at the
univariate analyses (HR 3.44, 95 % CI: 1.39–8.48, p =
0.007), and it was the only significant variable at the
multivariate assessment (HR 3.07, 95 % CI: 1.24–7.61,
p = 0.016). The consistency of the TAZpos/YAPpos
model was internally validated using a re-sampling
without replacement method. The replication rates,
defined as the percentage of Cox regression models
that yielded statistically significant results upon 100
replications in less-powered datasets (−20 % com-
pared with the original one), were 96 and 66 % with
statistical significance set at p <0.05 and p <0.01,
respectively.
Discussion
In the present analysis we reported on the predictive
and prognostic significance of TAZ and YAP expression,
assessed both at the tumor and the microenvironment
level, in a moderately-sized cohort of TNBC treated with
NACT. Results from this pilot study suggested that
TAZ/YAP expression might impact on both pCR rate
and long-term survival outcomes, and underscore the
complexity of the Hippo biology, which needs to be
carefully considered in the search for Hippo-related
prognostic and predictive biomarkers.
To our knowledge, this is the first report evaluating
TAZ and YAP jointly in TNBC and its microenviron-
ment and, more importantly, with a clear focus on pCR
and recurrence [15–17]. We are aware that our findings
are hypothesis-generating considering the retrospective
design of this study. Nevertheless, our results raised
some important considerations.
First, in BC great attention was put toward the identi-
fication of biomarkers related to the interactions of can-
cer cells with neighbor non-neoplastic cells. A number
of microenvironment-related biomarkers have been pro-
posed over the past decade, spanning from a wound-
response signature denoting the transcriptional response
of normal fibroblasts to serum [18] to the assessment of
stromal TILs in the neoadjuvant setting [19]. Reasoning
that the Hippo pathway is extensively associated with
the function of non-neoplastic cells involved in the
so-called tumor-stroma interplay, we envisioned a role
for the Hippo signal in this process. Consistently, the
identification of an association between YAP expres-
sion in both cancer cells and non-lymphocytic stro-
mal cells and reduced pCR rate provides clinical
ground for the feed-forward, self-reinforcing loop ne-
cessary for maintaining the CAF phenotype via YAP
Table 2 Univariate and multivariate logistic regression models evaluating the impact of the YAPpos/YAPstroma phenotype on
pCR (N = 61)
Univariate regression model Multivariate regression modela
OR (95 % CI) p-value OR (95 % CI) p-value
Age >49 vs ≤49 5.35 (1.51–19.03) 0.010 7.57 (1.81–31.65) 0.006
Stage III vs II 0.65 (0.19–2.16) 0.481
Grade III vs II 1.66 (0.54–5.12) 0.380
Ki-67 ≥60 vs <60 0.23 (0.07–0.76) 0.016 0.24 (0.06–0.94) 0.041
YAPpos/YAPstroma YAPpos/YAPstroma vs other combinations 5.23 (1.06–25.70) 0.042 7.13 (1.23–41.41) 0.029
aAdjusted for Age, Ki-67 and YAPpos/YAPstroma
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activation [8], and further highlights the role of CAFs
in chemotherapy resistance [20].
Second, given the exploratory nature of this study we
exclusively focused on Hippo transducers. Nevertheless,
a number of stimuli intersect the Hippo cascade, which ei-
ther encourage or restrain TAZ/YAP nuclear localization
and gene transcription. To appropriately address this
issue, a study where TAZ and YAP are evaluated together
with further candidate biomarkers has been planned,
envisioning the concomitant assessment of i) TAZ/YAP
targets (Axl and CTGF [2]), ii) Hippo-dependent and in-
dependent cues that feed TAZ/YAP activation, including
mechanisms involved in cell-cell adhesion and apical-
basal polarity [2], mechanotransduction [21], RHO
GTPases and the mevalonate pathway [22], and Wnt
signaling [23], and iii) Markers of specific cellular compo-
nents in the tumor microenvironment (e.g. CAFs,
immune cell subsets). Due to the limited amount of bio-
logical materials available after extensive routine patho-
logical assessment, we were unable to consider further
biomarkers for this study. Thus, a wider pathway analysis
that might enable us to identify a unique Hippo-related
biomarker profile able to inform on both pCR and survival
outcomes was recently initiated.
Fig. 2 Impact of the combined expression of TAZ and YAP on tumor recurrence. a OncoPrint showing the individual distribution of tumor
recurrences according to the combined nuclear expression of TAZ and YAP. Relapsed cases are indicated with the black line placed above the
OncoPrint. b Kaplan-Meier survival curves regarding disease-free survival in TAZpos/YAPpos tumors compared with the negative counterparts
Table 3 Uni- and multivariate Cox regression models of disease-free survival in TNBC patients (N = 57) considering a model of
double positivity for TAZ and YAP
Univariate regression model Multivariate regression modela
HR (95 % CI) p-value HR (95 % CI) p-value
Age >49 vs ≤49 1.17 (0.47–2.88) 0.738
Stage III vs II 1.17 (0.44–3.09) 0.751
Grade III vs I-II 1.71 (0.65–4.52) 0.278
pCR no vs yes 4.36 (1.00–18.99) 0.050 3.81 (0.87–16.71) 0.076
Ki-67 ≥60 vs <60 0.44 (0.16–1.17) 0.099
TAZ/YAP TAZpos/YAPpos vs other combinations 3.44 (1.39–8.48) 0.007 3.07 (1.24–7.61) 0.016
aAdjusted for pCR and TAZ/YAP
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Another aspect that deserves mention relates to the
biological significance of TAZ and YAP in BC. In this
setting, TAZ has been defined as an oncogene
promoting neoplastic transformation [24], chemotherapy
resistance [5, 25], EMT [4, 26], cancer stem cell (CSC)
self-renewal [4, 5], luminal to basal lineage switch [27],
and distant dissemination [5, 28]. Conversely, in preclin-
ical BC models YAP activation has been tied to opposite
functions. On the one hand, YAP was found to promote
neoplastic transformation [29–31], EMT [29], anchorage-
independent growth, retention of the cancer-associated
fibroblast (CAF) phenotype [8], and metastatization [32,
33]. On the other hand, tumor-suppressive activities have
been reported, such as the interaction with p73 [7], its
negative regulation mediated by oncogenic AKT and miR-
200 [6, 34], and frequent loss of heterozygosity at 11q22.2
[35]. Our study was not designed to provide mechanistic
insights into the molecular cues that modulate YAP acti-
vation in TNBC. Nevertheless, our results provide evi-
dence in support of the concept that, at least in TNBC,
YAP may elicit oncogenic functions. It is possible that
YAP acts in different way in distinct BC molecular sub-
types [3]. Indeed, Lehn et al. have recently reported on the
association between low YAP expression and decreased
recurrence-free survival in luminal A tumors [17]. Our re-
sults suggest an opposite interaction with pCR and long-
term outcomes in TNBC, and underlie the risk of carrying
out analyses in molecularly-unselected BC cohorts.
Intriguingly, survival data (DFS) raised the hypothesis
that, in TNBC, both TAZ and YAP are involved, and
possibly cooperate, in metastatic dissemination. A plaus-
ible explanation is that, albeit TAZ and YAP are closely
related proteins, they elicit a partial different array of
oncogenic activities. Consistently, the nature of up-
regulated genes upon their forced expression in cell lines
is partly different [36]. This is not surprising when con-
sidering the number of their transcriptional partners
that, beyond TEAD transcription factors, also include
SMAD and RUNX proteins [2]. Indeed, a partial differ-
ent interaction of TAZ/YAP with the aforementioned
transcriptional partners have been hypothesized [37],
and biochemical studies reported differences in the way
TAZ and YAP interact with TEAD4 [38].
Next, we have recently discussed possible strategies for
assessing TAZ and YAP by IHC [3]. In our opinion,
cytosolic expression should not be ignored, especially
when evaluation at different time points is not feasible.
Indeed, nuclear translocation of TAZ and YAP is dic-
tated by multiple cues and arguable oscillates over time
[2]. Nevertheless, in the present report we considered
tumors as positive or negative mostly on the basis of
cellular localization. This is due to the fact that the ma-
jority of the samples (~90 %) showed immunoreactivity
in either the nucleus or the cytoplasm (Additional file 1:
Table S1). Moreover, our study underlies the concept
that the assessment of TAZ and YAP should be ex-
tended to the non-neoplastic compartment, in order to
take into account the biological relevance of the Hippo
pathway in CAFs, TILs, and endothelial cells.
Finally, the growing interest of our group toward the
Hippo pathway in BC has fuelled a wave of studies in
other BC subtypes, such as hormone receptor-positive/
HER2-negative and hormone receptor-positive/HER2-
positive BC, and in male BC. Results from these studies
will provide a more exact picture on the clinical signifi-
cance of Hippo transducers in individual BC subtypes.
Conclusions
The combined expression of the Hippo transducer YAP in
tumor cells and non-lymphocytic stromal cells seemed as-
sociated with reduced efficacy of anthracycline-taxane-
based NACT in TNBC patients in terms of pCR rate.
Moreover, the nuclear co-expression of TAZ and YAP
may confer an increased risk of recurrence. Thus, Hippo-
related biomarkers deserve larger studies in TNBC.
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Additional file 1: Table S1. Expression of TAZ and YAP in cancer cells,
non-lymphocytic stromal cells, endothelial cells, and tumor-infiltrating
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Additional file 2: Table S2. associations between TAZ/YAP, assessed in
the tumor and in the microenvironment, and clinical-molecular features
and pCR (N = 61). (DOCX 12 kb)
Additional file 3: Table S3. Pattern of recurrence in the 19 TNBC
patients. (DOCX 12 kb)
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